These therapies function by stimulating the host immune response, targeting inhibitory pathways such as programmed death-ligand 1 (PD-L1), programmed death-1 (PD-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which are exploited by tumor cells to evade immune surveillance. This evidence concerns the gene CTLA4 and neoplasm.